CheckMate 227 第1部分:转移性非小细胞肺癌一线纳武利尤单抗联合伊匹木单抗对比化疗随访6年以上的无治疗生存
在CheckMate 227第1部分中,转移性非小细胞肺癌患者随机接受纳武利尤单抗联合伊匹木单抗或化疗,随访至少73.5个月时,联合组6年总生存率为20%对比化疗组11%,6年平均无治疗生存为12.2个月对比5.0个月(差值7.2,95%CI 5.4-9.2),且不受肿瘤PD-L1表达影响。
要点
- 6年时纳武利尤单抗联合伊匹木单抗组总生存率20%,化疗组11%。
- 6年平均无治疗生存联合组12.2个月对比化疗组5.0个月,差值7.2个月(95%CI 5.4-9.2)。
- 无≥3级治疗相关不良事件的无治疗生存联合组11.6个月对比化疗组4.8个月,差值6.9个月(95%CI 5.1-8.9)。
核心结论
- 纳武利尤单抗联合伊匹木单抗对比化疗改善了无治疗生存,且不受肿瘤PD-L1表达影响,支持其作为转移性非小细胞肺癌的有效一线治疗。
研究设计与样本
- CheckMate 227第1部分分析纳入所有随机患者(肿瘤PD-L1表达≥1%和<1%),无治疗生存通过限制性平均生存时间估计,为治疗终止时间与后续系统治疗或死亡时间Kaplan-Meier曲线之间的6年区域。
主要发现
- 随机化后6年(最小随访73.5个月,约6.1年),纳武利尤单抗联合伊匹木单抗组估计总生存率20%对比化疗组11%,无治疗患者比例13%对比2%。
- 6年平均无治疗生存联合组12.2个月对比化疗组5.0个月,差值7.2个月(95%CI 5.4-9.2),6年期间处于无治疗生存的时间占比17%对比7%。
- 6年无≥3级治疗相关不良事件的平均无治疗生存联合组11.6个月对比化疗组4.8个月,差值6.9个月(95%CI 5.1-8.9)。
- 平均无治疗生存时间占比在联合组从2年期间的15%增至6年期间的17%,化疗组从14%降至7%。
- 按肿瘤PD-L1表达分层观察到相似结果。
临床怎么用
- 原文结论支持纳武利尤单抗联合伊匹木单抗作为转移性非小细胞肺癌的有效一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Treatment-free survival (TFS) characterizes periods of disease control and durable clinical benefit after treatment discontinuation in patients treated with immunotherapy. In CheckMate 227 Part 1, nivolumab plus ipilimumab reported long-term durable overall survival (OS) benefit versus chemotherapy in patients with metastatic NSCLC. Here, we report updated long-term TFS results. METHODS: This analysis included all patients randomized (tumor programmed death ligand 1 [PD-L1] expression ≥1% and <1%). TFS was estimated as the restricted-mean survival time (between Kaplan-Meier curves for time to treatment discontinuation and time to subsequent systemic therapy or death) over 6 years after randomization. TFS was further divided into periods with or without ongoing toxicity (grade 3 or greater treatment-related adverse events) and estimated over 2 and 6 years after randomization. RESULTS: At 6 years after randomization (minimum follow-up: 73.5 months [∼6.1 years]), the estimated OS rate was 20% with nivolumab plus ipilimumab versus 11% with chemotherapy; 13% versus 2% of patients were treatment free. The 6-year mean TFS was 12.2 versus 5.0 months (difference 7.2 [95% confidence interval: 5.4-9.2]), with 17% versus 7% of the 6-year period spent in TFS. The 6-year mean TFS without grade 3 or greater treatment-related adverse events was 11.6 versus 4.8 months (difference, 6.9 [95% confidence interval: 5.1-8.9]). The proportion of mean TFS time increased from 15% of a 2-year to 17% of a 6-year period with nivolumab plus ipilimumab but decreased from 14% to 7% with chemotherapy. Similar results were observed by tumor PD-L1 expression. CONCLUSIONS: Nivolumab plus ipilimumab improved TFS versus chemotherapy, regardless of tumor PD-L1 expression, supporting its use as an efficacious first-line treatment for metastatic NSCLC.
引用
- Peters S, Regan MM, Paz-Ares LG, et al. Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1. J Thorac Oncol. 2025. PMID: 40473108. doi:10.1016/j.jtho.2025.05.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。